DYRK2 and central nervous system cancer: More and more studies are now showing that PML can act as a tumour initiator leading to carcinogenesis in chronic granulocytic leukaemia as well as in solid tumours such as glioma and breast cancer.The above indicates that PML may be used as a therapeutic target for the treatment of leukemia and solid tumors in the future.At the level of biological processes, DYRK2 and its related genes are involved in the cellular response to heat,which is essential for protection and recovery from cell damage.